CYCC - Koefisien bali modal nimbang wutah Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals (CYCC) is optimizing costs through flexible global supply chains for active substances. The financial model relies on grants and partnerships to develop leukemia treatments. The current PEG ratio clearly confirms the market valuation, where the actual value is 0.00. However, a liquidity deficit and uncertainty regarding fadraciclib test outcomes create significant risks for investors.

CYCC Rasio rega marang bathi tumrap wutah Cyclacel, Inc. (04.07.2022 - 12.09.2025)

Rincian metrik lan analitis perusahaan Cyclacel Pharmaceuticals (CYCC)

- rega saiki lan proyeksi nilai saham:

Bagan rega Cyclacel Pharmaceuticals, Inc.|CYCC - Target konsensus

- statistik kapitalisasi pasar:

Nilai pasar Cyclacel Pharmaceuticals Inc.|CYCC - Nilai Total Perusahaan

- indikator kapitalisasi buku:

Nilai Aset Bersih saben Saham Cyclacel|CYCC - Nilai Buku Perusahaan|Rasio Kapitalisasi marang Nilai Buku cyclacel.com|CYCC - Total Aset Perusahaan

- indikator beban kredit lan likuiditas emiten:

Rasio Total Utang marang Ekuitas Cyclacel Pharmaceuticals|CYCC - Utang jangka dawa marang ekuitas|Kewajiban jangka cendhak marang modal cyclacel.com|CYCC - Utang perusahaan|Rasio utang marang kapitalisasi buku Cyclacel Pharmaceuticals Inc.|CYCC - Utang jangka dawa perusahaan|Utang jangka cendhak Cyclacel|Likuiditas kritis cyclacel.com

- data bathi lan kelipatan valuasi:

CYCC - Penghasilan resik|Bathi resik sing dikarepake Cyclacel Pharmaceuticals|CYCC - Koefisien rega marang bathi|Pangali mangsa ngarep rega marang bathi Cyclacel, Inc.|CYCC - Pangali rega marang bathi tumrap wutah|Koefisien nilai perusahaan marang bathi operasional sadurunge panyusutan Cyclacel Pharmaceuticals Inc.|CYCC - Bathi operasional EBITDA|Bathi saben saham sajroning taun lumaku Cyclacel|CYCC - Bathi resik saben saham (EPS TTM)|Wutah bathi saben saham ing petungan tahunan sajrone rolas wulan pungkasan cyclacel.com|CYCC - Wutah bathi saben saham ing taun lumaku|Dinamika bathi saben saham sing diarepake ing taun ngarep Cyclacel Pharmaceuticals

Analisis fundamental perusahaan:Cyclacel Pharmaceuticals, Inc. CYCC

Produk asli Cyclacel Pharmaceuticals Inc.

The PEG ratio compares the current market multiple with net income growth, allowing for the determination of an asset's undervaluation relative to its expansion. While analyzing the current PEG level helps identify growth potential, for Cyclacel Pharmaceuticals (CYCC), this metric remains speculative, as the company is in the early stages of clinical trials and finances its operations through securities issuance.

Pesaing Cyclacel Pharmaceuticals